A Retrospective Case Series of the Lipid Effects of Switching From Omega-3 Fatty Acid Ethyl Esters to Icosapent Ethyl in Hyperlipidemic Patients

References

• . Research Center for Stroke and Heart Disease. Jacobs Neurological Institute. Statistics and Facts: Stroke and Heart Disease Facts and Statistics for Western New York. http://www.strokeheart.org/stats.html. Accessed March 31, 2014
   Google Scholar
• . Baigent C, Keech A, Kearney PM, ; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278
   PubMed Web of Science ®Google Scholar
• . Murad MH, Hazem A, Coto-Yglesias F, . The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis. BMC Endocr Disord. 2012;12:2
   PubMed Web of Science ®Google Scholar
• . Miller M, Stone NJ, Ballantyne C, ; American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011;123:2292–2333
   PubMed Web of Science ®Google Scholar
• . Vascepa [package insert]. Bedminster, NJ: Amarin Pharma Inc.; 2013
   Google Scholar
• . Lovaza [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2013
   Google Scholar
• . Havel RJ, Rapaport E. Management of primary hyperlipidemia. N Engl J Med. 1995;332:1491–1498
   PubMed Web of Science ®Google Scholar
• . Davidson MH, Stein EA, Bays HE, . COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:1354–1367
   PubMed Web of Science ®Google Scholar
• . Ballantyne CM, Bays HE, Kastelein JJ, . Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110:984–992
   PubMed Web of Science ®Google Scholar
• . Hilleman DE, Malesker MA. Potential benefits of icosapent ethyl on the lipid profile: case studies. Clin Med Insights Cardiol. 2014;8:13–15
   PubMedGoogle Scholar
• . Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. Curr Atheroscler Rep. 2011;13:474–483
   PubMed Web of Science ®Google Scholar
• . Boden WE, Probstfield JL, Anderson T, . Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365:2255–2267
   PubMed Web of Science ®Google Scholar
• . HPS2-THRIVE Collaborative Group. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur Heart J. 2013;34:1279–1291
   PubMed Web of Science ®Google Scholar
• . Armitage J. HPS2-THRIVE: randomized placebo-controlled trial of ER niacin and laropiprant in 25,673 patients with pre-existing cardiovascular disease. Paper presented at: Annual Scientific Session of the American College of Cardiology; March 9–11, 2013; San Francisco, CA
   Google Scholar
• . Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial). Am J Cardiol. 2011;108:682–690
   PubMed Web of Science ®Google Scholar
• . Yokoyama M, Origasa H, Matsuzaki M, ; Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369:1090–1098
   PubMed Web of Science ®Google Scholar
• . Stone NJ, Robinson J, Lichtenstein AH, . 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines [published online ahead of print November 12, 2013]. Circulation. doi:10.1016/j.jacc.2013.11.002
   Google Scholar
• . An International Atherosclerosis Society Position Paper: Global Recommendations for the Management of Dyslipidemia. Full Report. International Atherosclerosis Society. http://www.athero.org/aboutias.asp. Accessed January 10, 2014
   Google Scholar
• . , European Association for Cardiovascular Prevention and RehabilitationReiner Z, Catapano AL, ; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011;32:1769–1818
   PubMed Web of Science ®Google Scholar
• . American Diabetes Association. Standards of medical care in diabetes—2014. Diabetes Care. 2014;37( Suppl 1):S14–S80
   PubMed Web of Science ®Google Scholar
• . Jellinger PS, Smith DA, Mehta AE, ; AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis. American Association of Clinical Endocrinologists' Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis. Endocr Pract. 2012;18( Suppl 1):1–78
   PubMedGoogle Scholar